Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04492969 | Prospective Observation of Failure Patterns in NSCLC Treated With ICIs | unknown | — | 320 | Fudan UniversityOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03998085 | Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC | unknown | N/A | 40 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04489862 |
| αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors |
| unknown |
| Early Phase 1 |
| 10 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER |
| 1 |
| Jul 28, 2020 |
| clinicaltrials |
| NCT04487093 | Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03532698 | Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) | unknown | — | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT03758677 | Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT04482829 | TCM in the Treatment of Lung Adenocarcinoma | unknown | N/A | 144 | Henan University of Traditional Chinese MedicineOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT03923777 | Active Surveillance in Early Lung Cancer(ACTION-Lung) | unknown | N/A | 26 | University of Vermont Medical CenterOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04470076 | Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation(Neoafa) | unknown | Phase 2 | 30 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Jul 14, 2020 | clinicaltrials |
| NCT04461652 | The Effect of a Combined Drainage Strategy in Uniportal Upper Lung Lobectomy | unknown | N/A | 400 | Tongji UniversityOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03848611 | CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 20 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT01746251 | Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation | unknown | Phase 2 | 92 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03987867 | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04193098 | Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | unknown | Phase 1 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455984 | Multimodality Treatment Including Curative Resection of Advanced NSCLC | unknown | — | 190 | Medical University of ViennaOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04459663 | JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy. | unknown | Phase 2 | 50 | Li Zhang, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04455594 | Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC(ANSWER) | unknown | Phase 2 | 168 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453423 | Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2020 | clinicaltrials |
| NCT03634826 | Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).(MEDAL) | unknown | — | 200 | Peking University People's HospitalOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT03571360 | CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients | unknown | Phase 2 | 42 | Medical University of ViennaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04397926 | Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04419935 | Lymphadenectomy in NSCLC With and Without Adjuvant Therapy | unknown | — | 250 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04413227 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04115410 | PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study | unknown | — | 4,724 | Sungkyunkwan UniversityOTHER | 0 | May 28, 2020 | clinicaltrials |
| NCT04153799 | Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 | 11 | Sun Yat-sen UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04203485 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 762 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 8, 2020 | clinicaltrials |
| NCT04371796 | Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | May 1, 2020 | clinicaltrials |
| NCT04358562 | Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | unknown | Phase 2 | 240 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04355806 | Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors | unknown | — | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT03130192 | A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy | unknown | — | 60 | Chung Shan Medical UniversityOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT04339829 | An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | unknown | Phase 2 | 50 | Guangdong Association of Clinical TrialsOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT03706287 | Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC | unknown | Phase 1 / Phase 2 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT03940846 | CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology | unknown | — | 650 | Maastricht UniversityOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04333004 | Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | unknown | Phase 1 / Phase 2 | 40 | Xiaorong DongOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT04331626 | Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC | unknown | Phase 4 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Apr 2, 2020 | clinicaltrials |
| NCT04326751 | Evolution of Multiple Primary Lung Cancer (Evolution) | unknown | — | 20 | Peking University People's HospitalOTHER | 0 | Mar 30, 2020 | clinicaltrials |
| NCT03371992 | Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC(NO3DEXPL) | unknown | Early Phase 1 | 25 | Nilogen OncosystemsINDUSTRY | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04317651 | Crizotinib in ALK Rearranged Non-small-cell Lung Cancer(SPECIALK) | unknown | — | 500 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03764917 | NGS Combined With RNAseq on Tumor Immune Escape in NSCLC | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT03119519 | Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer. | unknown | Phase 2 | 148 | Southern Medical University, ChinaOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02076477 | The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）(OITROLC) | unknown | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT04306042 | A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy | unknown | — | 1,000 | Guangdong Association of Clinical TrialsOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT04306094 | Factors Determining the Prognosis in NSCLC Stage IV(LUPROG) | unknown | — | 217 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT04304638 | Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC | unknown | — | 450 | Chinese Academy of Medical SciencesOTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT04303130 | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC | unknown | Phase 2 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03130881 | Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. | unknown | Phase 1 | 60 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 31, 2020source: clinicaltrials